Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

PRG Nutraceuticals UK Launch

1 Oct 2009 10:34

RNS Number : 0408A
ReGen Therapeutics PLC
01 October 2009
 



1 October 2009

For immediate release

ReGen Announces PRG Nutraceuticals Limited UK Launch

ReGen Therapeutics Plc ('ReGen' or the 'Company') is pleased to announce that it has been notified by PRG Nutraceuticals Limited that it has launched Colostrinin™* as 'MemoryAid' in the UK.

Announcing the launch, PRG Managing Director Dr Peter Garrod said:-

"Every day we hear more evidence of how the population faces a terrible future as our brains become increasingly affected by conditions associated with getting old. MemoryAid contains a complex that we believe will help people to fight the onset of the problems that result from our brains undergoing the normal ageing process. Many years of research into the complex has shown that it promotes antioxidant activity, can reduce the toxicity of beta amyloid and protects the brain against the damaging effects of free radicals, all of which manifest themselves in the problems that occur as our brains naturally age. The complex has also been shown to increase the average lifespan of living cells and reduces premature ageing, which will also benefit consumers.

MemoryAid is targeted at a wide spectrum of people, both the older community, who may already be noticing that their brains are not functioning in the manner they are normally accustomed to, and at younger adults, who just want to protect themselves against memory deterioration in the future.

We are very excited by the benefits of MemoryAid and believe that it has a bright future on everyone's breakfast table."

MemoryAid is available on the internet at www.memoryaid.com or by contacting PRG on 01580 891349 or mobile 07785 740421.  

MemoryAid

Support for healthy brain ageing

Maintains normal mental function and supports healthy brain ageing.

Increases the average lifespan of living cells.

Reduces the aggregation and toxicity of beta amyloid, a feature of neurodegenerative conditions.

Protects the brain against the damaging effects of many free radicals

*Colostrinin™ is a proline-rich polypeptide complex that maintains normal mental function and supports healthy brain ageing.

For further information:

Dr Peter Garrod

PRG Nutraceuticals Ltd

Tel. 01580 891349 / 07785 740421

Percy Lomax ReGen Therapeutics Plc Tel No 020 7153 4920

Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel No 020 7628 3396

Nick Bealer/David Scott Alexander David Tel No 020 7448 9820 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGCBDGIDGGGCB
Date   Source Headline
2nd Mar 201812:09 pmRNSStatement re broker
22nd Jan 20187:00 amRNSPlacing
16th Jan 20187:00 amRNSPlacing
15th Dec 20177:00 amRNSPlacing and Issue of Equity
8th Dec 20177:00 amRNSMilciclib Phase 2a Trial Update
27th Nov 20177:00 amRNSPlacing
23rd Nov 20177:00 amRNSPhase II Clinical Trial Update
20th Nov 20177:00 amRNSSubscription
29th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
6th Sep 20177:00 amRNSA Proprietary Oral Formulation of Foralumab
31st Aug 201711:07 amRNSGrant of options - Director's dealing
16th Aug 20177:00 amRNSConversion of outstanding loan notes
28th Jul 20177:00 amRNSPublication of Research Article on Foralumab
19th Jul 20177:00 amRNSInitiation of a Phase IIa Clinical Trial
12th Jul 20177:00 amRNSProposed changes to CLNs and Warrant Terms
29th Jun 201711:21 amRNSResult of AGM
12th Jun 20177:00 amRNSAppointment of Dr Kunwar Shailubhai as CEO
8th Jun 201710:02 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
8th Jun 20178:14 amRNSBcl-3 pre-clinical update and Director's dealing
1st Jun 20177:00 amRNS2016 Annual Report and Accounts and notice of AGM
23rd May 20177:00 amRNSFinancial Results for Year Ended 31 December 2016
24th Apr 20177:14 amRNSAnnounces Approval of a Phase II Clinical Trial
21st Apr 20177:00 amRNSAnnounces Publication of Milciclib Clinical Trial
24th Mar 20177:00 amRNSExercise of Warrants & Issue of Equity
14th Mar 20177:00 amRNSArun Sanyal appointed to Scientific Advisory Board
16th Jan 20177:00 amRNSWarrant Expiry - Reminder
3rd Jan 20177:00 amRNSTiziana Life Sciences in-licenses NI-1201
16th Nov 20167:00 amRNSNew Data with Foralumab
7th Nov 201612:29 pmRNSGrant of options
29th Sep 20167:00 amRNSHalf-year Report
15th Sep 20167:00 amRNSConfirmation of Capital Reduction
18th Aug 20167:00 amRNSChange of Registered Office
18th Jul 20167:00 amRNSTiziana acquires a unique bio-repository
30th Jun 201612:47 pmRNSResult of AGM
29th Jun 20167:00 amRNSIssue of Equity
10th Jun 201610:18 amRNSGrant of options and realisation bonus
7th Jun 20167:00 amRNSFinal Results
1st Jun 20167:00 amRNSPartnership with Cardiff Researchers Wins Award
19th May 20167:00 amRNSJournal review of anti - CD3 monoclonal antibodies
4th May 20167:00 amRNSAppointment of Dr. Robert Evans
28th Apr 20167:00 amRNSExercise of Warrants & Issue of Equity
4th Apr 20167:00 amRNSChief Financial Officer Appointed
15th Mar 20167:00 amRNSCo-Founder and NED Prof Chris McGuigan Passes Away
16th Feb 20164:40 pmRNSSecond Price Monitoring Extn
16th Feb 20164:35 pmRNSPrice Monitoring Extension
13th Jan 20167:00 amRNSFund raising
11th Jan 20167:00 amRNSDevelopment plans for foralumab & SAB appointments
8th Jan 20167:00 amRNSUpdate on Tiziana's Bcl-3 inhibitor
9th Dec 20158:00 amRNSAppoints James F. Tripp as Chief Operating Officer
8th Dec 20157:00 amRNSFund raising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.